Insulin/pramlintide - Amylin/JDRF

Drug Profile

Insulin/pramlintide - Amylin/JDRF

Alternative Names: Pramlintide/insulin

Latest Information Update: 27 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amylin Pharmaceuticals; JDRF
  • Developer AstraZeneca; JDRF
  • Class Insulins; Macromolecular substances; Pancreatic hormones; Proteins
  • Mechanism of Action Amylin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 01 Aug 2016 AstraZeneca completes a phase I trial for Type-1 diabetes mellitus in USA (NCT02500979)
  • 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
  • 10 May 2011 Early research in Type-1 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top